Exicure Inc (XCUR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Exicure Inc stock (XCUR) is currently trading at $4.61. Exicure Inc PS ratio (Price-to-Sales) is 74.42. Analyst consensus price target for XCUR is $2.00. WallStSmart rates XCUR as Sell.
- XCUR PE ratio analysis and historical PE chart
- XCUR PS ratio (Price-to-Sales) history and trend
- XCUR intrinsic value — DCF, Graham Number, EPV models
- XCUR stock price prediction 2025 2026 2027 2028 2029 2030
- XCUR fair value vs current price
- XCUR insider transactions and insider buying
- Is XCUR undervalued or overvalued?
- Exicure Inc financial analysis — revenue, earnings, cash flow
- XCUR Piotroski F-Score and Altman Z-Score
- XCUR analyst price target and Smart Rating
Exicure Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Exicure Inc (XCUR) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Exicure Inc (XCUR) Key Strengths (1)
Revenue surging 928.00% year-over-year
Exicure Inc (XCUR) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 74.4x annual revenue
Very low institutional interest at 2.33%
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.2x book value
Supporting Valuation Data
Exicure Inc (XCUR) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 928.00%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (74.42), Price/Book (4.23) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -217.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -217.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 928.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
XCUR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
XCUR's Price-to-Sales ratio of 74.42x trades 100% above its historical average of 37.28x (73th percentile), historically expensive. The current valuation is 59% below its historical high of 182.57x set in Nov 2019, and 148740% above its historical low of 0.05x in May 2022. Over the past 12 months, the PS ratio has compressed from ~178.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Exicure Inc (XCUR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Exicure Inc is in a high-growth phase, prioritizing rapid expansion over margins.
Key Findings
Revenue growing at 928% YoY. This pace significantly outperforms most BIOTECHNOLOGY peers.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Exicure Inc maintain 928%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 4.19, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Exicure Inc.
Bottom Line
Exicure Inc is a high-conviction growth story with revenue accelerating at 928% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(4 last 3 months)
| Insider | Type | Shares |
|---|---|---|
MILLER, JOSH Chief Accounting Officer | Sell | -8 |
| Insider | Type | Shares |
|---|---|---|
EXICURE, HITRON INC. 10% Owner | Sell | -258,367 |
| Insider | Type | Shares |
|---|---|---|
EXICURE, HITRON INC. 10% Owner | Sell | -734,747 |
| Insider | Type | Shares |
|---|---|---|
EXICURE, HITRON INC. 10% Owner | Sell | -741,272 |
Data sourced from SEC Form 4 filings
Last updated: 10:09:18 AM
About Exicure Inc(XCUR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. The company is headquartered in Chicago, Illinois.